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Abstract

Background: The urokinase plasminogen activation (uPA) system is a crucial pathway for tumour invasion
and establishment of metastasis. Although there is good evidence that uPA system expression is a clinically
relevant biomarker in some solid tumours, its role in gastroesophageal cancer is uncertain. Results: We
identified 22 studies encompassing 1966 patients which fulfilled the inclusion criteria. uPA, uPAR, or PAI-1
expression is significantly associated with high risk clinicopathological features. High uPA expression is
associated with a shorter RFS (HR 1.90 95% 1.16-3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74-2.80, p <
0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI 1.82-2.69, p < 0.0001). High
PAI-1 expression is associated with shorter RFS (HR 1.96 96% CI 1.07-3.58, p = 0.03) and OS (HR 1.84
95%CI 1.28-2.64, p < 0.0001). There was no significant association between PAI-2 expression and OS (HR
0.97 95%CI 0.48-1.94, p < 0.92) although data was limited. Materials and Methods: We undertook a
systematic review evaluating expression of uPA, urokinase plasminogen activator receptor (uPAR),
plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/
SerpinB2) on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas. We
performed a meta-analysis of clinicopathological associations, overall survival (OS) and recurrence free
survival (RFS). Conclusions: We conclude that the uPA system is a clinically relevant biomarker in primary
gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1 associated with higher risk disease
and poorer prognosis. This also highlights the potential utility of the uPA system as a therapeutic target for
improved treatment strategies.
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ABSTRACT
Background: The urokinase plasminogen activation (uPA) system is a crucial
pathway for tumour invasion and establishment of metastasis. Although there is good
evidence that uPA system expression is a clinically relevant biomarker in some solid
tumours, its role in gastroesophageal cancer is uncertain.
Results: We identified 22 studies encompassing 1966 patients which fulfilled
the inclusion criteria. uPA, uPAR, or PAI-1 expression is significantly associated
with high risk clinicopathological features. High uPA expression is associated with a
shorter RFS (HR 1.90 95% 1.16–3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74–2.80,
p < 0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI
1.82–2.69, p < 0.0001). High PAI-1 expression is associated with shorter RFS (HR
1.96 96% CI 1.07–3.58, p = 0.03) and OS (HR 1.84 95%CI 1.28–2.64, p < 0.0001).
There was no significant association between PAI-2 expression and OS (HR 0.97
95%CI 0.48–1.94, p < 0.92) although data was limited.
Materials and Methods: We undertook a systematic review evaluating expression
of uPA, urokinase plasminogen activator receptor (uPAR), plasminogen activator
inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/SerpinB2)
on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas.
We performed a meta-analysis of clinicopathological associations, overall survival
(OS) and recurrence free survival (RFS).
Conclusions: We conclude that the uPA system is a clinically relevant biomarker
in primary gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1
associated with higher risk disease and poorer prognosis. This also highlights the
potential utility of the uPA system as a therapeutic target for improved treatment
strategies.
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INTRODUCTION

[5]. High expression of uPAR on the invasive front of
tumours facilitates invasion and other roles in cellular
migration and angiogenesis [6]. uPAR expression may
be a suitable marker for the onset of invasion of both
gastro-intestinal and breast cancer as it is expressed only
on invasive carcinomas, not premalignant states such as
Barrett’s oesophagus [7].
Urokinase-type plasminogen activator is efficiently
inhibited by two subtypes of serpin (serine proteinase
inhibitor) family members, plasminogen activator
inhibitor-1 (PAI-1/SerpinE1) and –2 (PAI-2 /SerpinB2).
Both form a covalent complex with uPA/uPAR leading
to internalisation of the entire complex [8] . Although
believed to have a physiological role as an inhibitor of
the uPA system, PAI-1 has a paradoxical protumourgenic
role, increasing tumour invasion and angiogenesis, and
correlated with poor prognosis [9]. The role of PAI-2 in
cancer is less clear. Although both PAIs mediate uPA/
uPAR endocytosis, the uPA-PAI-2 complex interacts with
endocytosis receptors with different binding kinetics to
those of uPA:PAI-1 and without stimulating intracellular
signalling events over and above that of uPA binding to
uPAR [10].
While the uPA system is expressed on both cancer
cells and the supporting stroma, higher expression is
seen on tumour cells, and is postulated that the tumour
cell specific uPA/uPAR explains the aggressive biology
exhibited by these cancers, and is more relevant for
prognostic outcomes [11–14]. Expression of the uPA
system has been shown to be an important prognostic
marker in a variety of cancers including breast cancer

Gastroesophageal cancer is a common and lethal
malignancy, marked by modest response to systemic
therapies [1]. A deeper understanding of molecular events
characterising carcinogenesis, invasion, progression and
metastasis is central for the development of novel therapies.

The uPA system
A key process in the development and progression
of cancer, including establishment of metastatic disease,
is the invasion of malignant cells into normal tissue. The
plasminogen activation system, particularly the urokinasetype plasminogen activator (uPA) system, is critical for
tumour-associated proteolysis to breakdown extracellular
matrix (ECM) and basement membranes barriers [2]. The
uPA system has a defined role in tissue degradation and
extravascular fibrinolysis, and is responsible for most of
the activated plasminogen associated with cancer invasion
and metastasis [2, 3] (Figure 1).
The uPA protein is secreted as a zymogen and
activated on high affinity binding to its specific cell
surface receptor uPAR. Once activated, uPA catalyses the
activation of co-localised plasminogen to plasmin, which
in turn directly degrades components of the ECM, and
promotes further degradation and tissue remodelling by
activating pro-metalloproteinases and by releasing, thus
activating, latent growth factors from the ECM [4].
The uPA receptor (uPAR) is anchored to the plasma
membrane, localising the uPA system to the cell surface

Figure 1: The uPA system. Schematic representation of the urokinase plasminogen activation (uPA) system. The membrane bound

urokinase receptor (uPAR) binds circulating inactive pro-uPA, facilitating the activation of pro-uPA to uPA which subsequently converts
co-localised plasminogen to plasmin that can directly degrade components of the extracellular matrix (ECM) and activate pro-matrix
metalloproteases (MMP) to further break down ECM. Plasminogen activator inhibitors 1 or 2 (PAI-1, PAI-2) are efficient endogenous
inhibitors of uPA.
www.impactjournals.com/oncotarget
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[15], lung cancer [16], and colorectal cancer [17], with the
combination of uPA and PAI-1 expression recommended
to be incorporated into routine clinical care of node
negative breast cancer [18].
In this study we aim to perform a comprehensive
systematic review of expression of the uPA system
encompassing uPA, uPAR, PAI-1, and PAI-2 in primary,
resectable gastro-oesophageal cancer, and undertake
meta-analyses of prognostic outcomes (recurrence free
survival and overall survival), and association with
relevant clinicopathological variables. To the best of our
knowledge, this is the first meta-analysis to examine and
compare the expression of these key components of uPA
system in primary gastro-oesophageal cancer.

population [7, 12, 13, 30–40] and 11 studies did not report
completeness of followup [7, 12, 13, 30–33, 36, 38, 39, 41].
Most studies adequately reported method of measurement of
the uPA system, although 5 studies did not report whether
there was a second independent reviewer or blinding to
clinical information [13, 35, 39, 40, 42]. The followup
protocol was underreported in 14 studies [7, 11–13, 30–
36, 38–40], although this is unlikely to bias the results for
overall survival analyses. Most studies did not report details
of the surgical, medical, or radiation treatments received by
patients, and were Urokinase plasminogen activator (uPA).

Urokinase plasminogen activator (uPA)
uPA expression rates

RESULTS

Expression of uPA was evaluated in 13 studies (1254
patients). The mean expression of uPA was 52.8%, but had
a large range (from 23% to 91%). There was no significant
difference in mean expression for IHC (60.7%) and ELISA
(45.6%) (p = 0.10).

Included studies
The trial flow is provided in Figure 2. We identified
267 reports matching criteria for inclusion in the study,
of which 109 were selected for abstract review, and 60
subsequently for full text review. Forty one studies
(including 2689 patients) fulfilled criteria for inclusion
in the systematic review, with 22 studies (1966 patients)
providing sufficient data for inclusion in the formal
quantitative meta-analysis: 19 studies were excluded
for the following reasons: 12 studies did not examine
prognostic or clinicopathological associations, 3 reports
were matched case control studies, and 4 studies reported
insufficient published data to derive a HR.
The characteristics of the included studies are
summarized in Supplementary Table 1. Eighteen studies
evaluated uPA system expression in gastric cancer (1732
patients), one study included oesophageal, junctional and
gastric cancers (39 patients), and two studies examined
oesophageal cancer only (105 patients). Expression of the
uPA system was assessed using immunohistochemistry (IHC,
12 studies, 1273 patients), enzyme-linked immunosorbent
assay (ELISA, 5 studies, 344 patients), reverse transcription
polymerase chain reaction (RT-PCR, 3 studies, 153 patients),
or in-situ hybridisation (ISH, one study, 105 patients).
Hazard ratios directly extracted for 3 studies
[7, 11, 22]. The multivariate HR was used when univariate
value was not provided [22]. When only subgroup outcome
data (tumour core or peripheral zone) were available, the
results for peripheral “invasion” zone were used [7, 11].
Hazard ratios were estimated for the remaining studies
using published data. 4 studies reported a “non-statistically
significant OS” result for uPA system expression, but did not
publish sufficient data for inclusion in meta-analysis [23–26].

uPA and clinicopathological associations
uPA expression is significantly associated with poorer
clinicopathological features in resected gastroesophageal
cancer including: Advanced T stage (T3/4 vs T1/2) (OR
2.79 95% CI 1.80–4.32, p < 0.0001), nodal metastases
(OR 2.30 95% CI 1.63–3.51, p < 0.0001), liver
metastases (OR 6.77 95% CI 2.70–16.96, p < 0.0001),
peritoneal metastases(OR 2.09 95% CI 1.29–3.36, p =
0.003), lymphatic invasion (OR 2.28 95% CI 1.31–3.97,
p = 0.0003), and vascular invasion (OR = 2.43 95%
CI 1.53–3.86, p = 0.0002) (5 studies, 522 patients,
Supplementary Figure 1). There is no significant association
with histology (poorly differentiated vs well differentiated).
uPA expression and prognosis
uPA expression was significantly associated with
a worse RFS (3 studies, 467 participants, HR 1.90 95%
1.16–3.11, p = 0.01) (see Supplementary Figure 2). There was
no significant difference in RFS seen between studies using
IHC (HR 1.77) or ELISA (HR 2.36) to assess uPA expression
(test for subgroup differences Chi2 = 0.37, p = 0.54).
uPA expression is significantly associated with
poorer OS (12 studies, 1094 participants, HR 2.21 95%
CI 1.74–2.80, p < 0.0001) (see Figure 4). There was no
significant difference in OS between studies which used
IHC (HR 1.94) or ELISA (HR = 2.99) to assess uPA
expression (p = 0.38). Sensitivity analysis showed similar
results when analysis was restricted to gastric cancer only
(HR 2.07, p < 0.00001).

Urokinase plasminogen activator receptor (uPAR)

Bias risk

uPAR expression rates

The risk of bias summary is summarized in Figure 3.
Only 4 studies [22, 27–29] were deemed low risk in all bias
domains. Fourteen studies did not clearly define the study
www.impactjournals.com/oncotarget
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uPAR expression and prognosis

14–90%), with similar mean expressions seen in IHC
(56.8%) and ELISA/RT-PCR (56.7%).

Only one study provided data for uPAR expression
and RFS [42], showing a shorter RFS with uPAR
expression (203 patients, HR 2.69, p = 0.03).
uPAR expression is associated with poorer OS
(11 studies, 1036 patients, HR 2.19 95% CI 1.80–2.66,
p < 0.0001) (Figure 5). There was no significant difference
in OS seen between studies which used IHC (HR 2.13),
ISH (HR 2.34), ELISA (HR 2.19), or RT-PCR (2.66) to
assess uPAR expression (p = 0.96).

uPAR expression and clinicopathological associations
uPAR
expression
on
primary
resected
gastroesophageal cancer is significantly associated with
poorer clinicopathological features including: advanced
TMN stage (stage III/IV vs I/II, OR 3.41 91% CI 1.55–7.53,
p = 0.002), advanced T stage (OR 2.33 95% CI 1.53
to 3.56, p < 0.0001), nodal metastases (OR 2.52 95%
CI 1.70–3.72, p < 0.0001), liver metastases (OR 2.53 95%
CI 1.25–5.13, p = 0.010), peritoneal metastases (OR 3.15
95% CI 1.87–5.28, p < 0.0001), lymphatic invasion
(OR 2.82 95% CI 1.74–4.59, p < 0.0001) and vascular
invasion (OR 3.85 95% CI 2.53–5.88, p < 0.0001) (six
studies, 589 patients, Supplementary Figure 3). There is
no significant association seen with histology (p = 0.6).

Plasminogen activator inhibitor-1 (PAI-1)
PAI-1 expression rate
Twelve studies (1031 patients) examined PAI-1
expression. Mean PAI-1 expression was 53.3%, with no

Figure 2: Study selection flow diagram. HR –hazard ratio; OS–overall survival; RFS–recurrence free survival.
www.impactjournals.com/oncotarget
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p = 0.47) and ELISA (HR 2.94, p < 0.0001) or RT-PCR
(HR 2.83, p < 0.0001) (p = 0.02).

statically significant difference in expression between IHC
(61.8%) and RT-PCR/ELISA (44.7%) (p = 0.1).
PAI-1 expression and clinicopathological variables

Plasminogen activator inhibitor-2 (PAI-2)

PAI-1 expression on primary resected gastroesophageal
cancer is significantly associated with poorer
clinicopathological features including: advanced T stage (OR
2.59 95% CI 1.61 to 4.18, p < 0.0001), nodal metastases (OR
2.03 95% CI 1.27–3.22, p < 0.003), lymphatic invasion (OR
2.09 95% CI 1.31–3.34, p < 0.004) and vascular invasion
(OR 1.90 95% CI 1.20–3.03, p < 0.007) (three studies, 317
patients, Supplementary Figure 4). There was no significant
association of PAI-1 expression with presence of liver
metastases (OR 0.52, p = 0.18), peritoneal metastases (OR
1.38, p = 0.31), or histology (OR 0.93, p = 0.74).

PAI-2 expression rate
Two studies (145 participants) assessed PAI-2
expression (all using IHC) (refer to Supplementary
Table 1). Mean expression was 57.5%.
PAI-2 expression and clinicopathological variables
There were no studies with sufficient data analyzing
PAI-2 expression and clinicopathological variables for
inclusion in the meta-analysis.
PAI-2 expression and prognosis

PAI-1 expression and prognosis

No studies published data on PAI-2 expression
and RFS. There was no significant association of PAI-2
expression and OS (2 studies, 145 participants, HR 0.97
95%CI 0.48–1.94, p < 0.92, Supplementary Figure 6).

PAI-1 expression is associated with shorter RFS
(3 studies, 467 patients, HR 1.96 96% CI 1.07–3.58, p =
0.03) (Supplementary Figure 5). There was no significant
difference in RFS between studies which used IHC or
ELISA to detect PAI-1 expression (p = 0.86)
PAI-1 expression is significantly associated with a
shorter OS (10 studies, 839 participants, HR 1.84 95%CI
1.28–2.64, p < 0.0001, Figure 6). Pre-specified subgroup
analysis showed a significant difference between studies
which assessed PAI-1 expression using IHC (HR 1.20,

Publication bias
Examination of the funnel plots for the OS analysis
for uPA, uPAR and PAI-1 showed asymmetrical plots for
all analyses, suggesting absence of smaller negative trials
(example plot for uPA provided in Supplementary Figure 7).

Figure 3: Risk of bias summary. For each bias domain: green = “low risk” means that sufficient data was available to allow assessment

of quality and fulfilled criteria for each domain, and accordingly is deemed low risk of bias. Orange = “unclear risk” means that insufficient
data was presented to adequately assess the quality of the domain and accordingly the study has potentially high risk of bias. There were
no studies deemed high risk of bias.
www.impactjournals.com/oncotarget
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DISCUSSION

this result should be interpreted with caution due to the
following important limitations in our study.
Firstly, only four of the included studies were
deemed low risk for all bias domains as assessed by the
QUIPS tool. In particular, most studies did not report
the treatments patients received which is an important
potential source of confounding for RFS and OS analyses.
Additionally, tumours with higher risk clinicopathologic
features could reasonably be expected to be more likely
to have received neoadjuvant treatment prior to surgery,
which may in turn have impacted on the expression of the
uPA system. Despite this, it should be noted that similar
results were seen in studies deemed low and high risk of
study confounding, and heterogeneity was low in both
the uPA and uPAR OS meta-analyses (I2 = 31% and 0%
respectively, see Figures 4 and 5).
Secondly, there is evidence of underreporting of nonsignificant results. This is demonstrated by both the funnel
plot, as well the selective reporting of only statistically
positive findings from included studies. This important bias
will cause an overestimation of the effect of expression.
Thirdly, as demonstrated above, tumours that
expressed uPA, uPAR and PAI-1 had higher risk features,

This meta-analysis confirms the clinical utility of the
uPA system as a biomarker in resected gastro-oesophageal
adenocarcinoma.
There is good evidence that high expression of
uPA, uPAR, and PAI-1 is associated with most high
risk clinicopathological features, including advanced
T stage, presence of nodal and distant metastases, and
lymphovascular invasion, in primary gastro-oesophageal
adenocarcinoma. This supports the central role of the uPA
system in tumour invasion and metastasis. In contrast,
there was no significant association of expression found
with poorly differentiated histology, consistent with
previously published work which shows that epithelial cell
uPA system expression is higher in malignant than benign
tissue, but decreases as tumour becomes more poorly
differentiated, with a corresponding increase in stromal
expression [43].
We also demonstrated that uPA, uPAR, and PAI-1
expression is associated with poorer prognosis in resected
gastro-oesophageal cancer, with both a shorter RFS and
OS in tumours which expressed these markers. However

Figure 4: Pooled estimate of hazard ratio (HR) for uPA expression and overall survival (OS). Pooled estimate of hazard
ratio (HR) for overall survival. The square on each bar represents the HR for an individual trial, and the bar shows the 95% confidence
interval (CI). The diamond represents a pooled estimate with the centre of the diamond giving the HR estimate, and the extremes of the
diamond representing the 95% CI. 24.
www.impactjournals.com/oncotarget
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and RT-PCR (HR 2.83, p = 0.0007). This highlights the
importance of the stromal production of PAI-1 within the
tumour microenvironment [9], as only methods that took into
account both stromal and tumour PAI-1 showed statistically
significant prognostic outcomes. It has been postulated that
in contrast to uPAR, fibroblasts and endothelial cells provide
the major source of PAI-1 within the tumour tissue [45]. It
is possible that the PAI-1 detected on the tumour cells by
IHC may be explained by internalization and accumulation
of stromal produced uPA-PAI-1 complexes mediated by
tumour uPAR [46]. No IHC studies examined the association
between stromal PAI-1 expression and prognostic outcomes
in gastro-oesophageal cancer.
All IHC study results used in the meta-analysis
were restricted to tumour cell expression only. Similar to
other cancers, uPA system expression was highest at the
invasive front of the tumour [7, 11, 12, 31]. Only four

and would be expected to recur or progress sooner than
tumours that did not. The apparent difference in prognostic
outcomes may be due to unequal baseline characteristics
of the included participants.
We did not show a significant difference in the
prognostic outcomes between studies which used a tumour
cell specific technique (e.g. IHC) compared to whole
tissue lysates (e.g. RT-PCR, ELISA) for uPA and uPAR.
This is consistent with other studies which have shown
correlation between IHC score and median ELISA value,
and supports the cancer cells as a major source of uPA and
uPAR expression in the tumour tissue [44].
In contrast, there was a significant different in the
expression methodology subgroups in the analysis for
PAI-1 and OS (p = 0.02), with a non-significant outcome
seen in studies using IHC (HR 1.20, p = 0.47), compared
to significant results with ELISA (HR 2.94, p < 0.0001)

Figure 5: Pooled estimate of hazard ratio (HR) for uPAR expression and overall survival (OS).
www.impactjournals.com/oncotarget
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studies reported stromal expression of the uPA system
[7, 11, 12, 42]. Results were conflicting, with only one study
showing a significant association of OS with macrophage
uPAR expression on the invading zone at the periphery of
the tumour [7]. In colorectal cancer, high uPAR expression
on macrophages in the tumour core, rather than the
periphery, is an independent predictor of poor prognosis
[47]. These studies suggest an important supporting role
of the tumour associated macrophages within the tumour
microenvironment. The contrasting pattern of high uPAR
expression (core versus peripheral) may be due to differing
phenotypes of the subpopulations of tumour preventing (M1
macrophages) and tumour promoting (M2 macrophages)
macrophages within the heterogeneous tumour bulk [48]
. Further work is required to elucidate the biology of the
stroma in gastrointestinal cancers.
We were unable to show any significant associations
with PAI-2 expression with either clinicopathological
features or prognostic outcomes, as available data was
much more limited. Similarly only 3 studies examined
oesophageal cancer, which limits applicability of our results
to this subgroup. Sensitivity analysis did not show a different
result when oesophageal cancer was excluded from analysis.

In conclusion, expression of the uPA system is
a clinically relevant biomarker in gastroesophageal
cancer. There is good evidence to support the association
of uPA, uPAR, and PAI-1 expression and high risk
clinicopathological features. While we found a statistically
significant association between uPAR, uPAR and PAI-1
expression and poorer prognosis, our results are tempered
by methodical limitations discussed above. Our findings
also highlight the potential utility of the uPA system as a
therapeutic target for improved treatment strategies.

MATERIALS AND METHODS
Methods are reported according to Preferred
Reporting for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [19].

Study eligibility/selection criteria
We included all studies which examined the
following components of the urokinase plasminogen
activation system uPA, uPAR, PAI-1 or PAI-2, in resected
primary esophageal, gastroesophageal junction, or

Figure 6: Pooled estimate of hazard ratio (HR) for PAI-1 expression and overall survival (OS).
www.impactjournals.com/oncotarget
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gastric adenocarcinomas. Other tumour pathologies were
excluded. A ll methods of assessing expression, including
reverse transcription polymerase chain reaction (RTPCR), enzyme-linked immunosorbent assay (ELISA),
in-situ hybridization (ISH), and immunohistochemistry
(IHC) were included. For inclusion in the metaanalysis, studies were required to report the association
of the following outcomes with uPA system expression:
overall survival (OS), recurrence-free survival (RFS), or
clinicopathological variables.
Two authors (DB, JC) independently performed the
search and screened the studies. The primary outcome was
OS; secondary outcomes were RFS, and correlation of
clinicopathological variables with uPA system expression.

and loss to followup; prognostic factor measurement;
outcome measurement; study confounding; and statistical
analysis and reporting [20].

Statistical analysis
We extracted the hazard ratio (HR) and their
95% confidence intervals (CI) for time-to-event
outcomes including RFS and OS. If both univariate and
multivariate HR were published the univariate results
were preferentially used. Where no HR was provided in
published data, it was estimated from available results or
Kaplan-Meier survival curves using previously described
methods [21].
HRs were synthesized using the generic inverse
variance method and a random effect model using
RevMan5.1 analysis software. Statistical heterogeneity
was assessed using the I2 statistic. We performed prespecified subgroup analysis for overall survival for:
primary location (gastric or oesophageal), cancer cell
specific expression (using IHC) compared to whole cell
lysis (using RT-PCR/ELISA).
Clinicopathological associations were summarized
using odds ratios (OR) derived from published results.
This analysis was limited to studies using IHC, as other
methods presented expression results as means, rather than
percentage of patients expressing. Expression rates were
described with mean and range, and compared using the
student’s t-test.

Study search strategy
We searched the following databases in February
2015 for all trials fulfilling the above criteria: Medline
(1950–present); EMBASE (1966–present); Cochrane
Central Register of Controlled Trials, and Cochrane
Database of Systematic Reviews; PubMed.
To maximize sensitivity the following search terms
were used: Stomach Neoplasms (MESH) OR Esophageal
neoplasms (MESH) OR Gastrointestinal neoplasms
(MESH) OR Gastric cancer.mp OR Gastric carcinoma.
mp OR esophageal cancer.mp OR oesophageal cancer.
mp OR gastroesophageal cancer.mp AND Receptors,
urokinase plasminogen activator (MESH) OR Urokinasetype plasminogen activator (MESH) OR Plasminogen
activator inhibitor 1 (MESH) OR Plasminogen activator
inhibitor.mp OR PAI-1.mp OR PAI-2.mp OR Urokinase*
plasminogen.mp OR uPA*.mp. Reference lists of included
studies and review articles were hand searched. The search
was restricted to studies published in English.
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